Option chain shows key data for CARISMA Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CARISMA Therapeutics.

CARISMA Therapeutics (NASDAQ:CARM) Stock, Option Chain

CARISMA THERAPEUTICS INC

CARISMA Therapeutics

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Inflation

Earnings

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CARM

DPRO

HSDT

LDTC

NAOV

VTAK

Dow Rises Over 50 Points; US Inflation Rate Increases In May

AIHS

AMSC

ARAI

CNET

GELS

GETY

GLYC

GTLB

IMNN

INEO

KBSX

NCNA

SFIX

VXRT

YSXT

Why Stitch Fix Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Wall-street-shutter3

Equities

BIYA

EVGN

WLGS

US Stocks Mixed; JM Smucker Shares Plunge After Q4 Results

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics Inc

CARMAT ORD by Carmat

CARMELL CORPORATION WT EXP

CarMax Inc

Carmila SA

Penny Stocks

Press Releases

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Carisma Therapeutics Provides Corporate Updates

ABBV

AVIR

COYA

MEIP

MRNA

RIBT

SYBX

TSX:PHO

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Boundless Bio

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

Elevation Oncology

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Ernexa Therapeutics

FibroGen

Generation Bio

Imunon

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

Nanoviricides

Ovid Therapeutics

Q32 Bio

Tenax Therapeutics

D. Boral Capital

Baird

Evercore ISI Group

EF Hutton

Capital One

Comments

CARISMA Therapeutics

CARISMA Therapeutics (CARM) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell